Literature DB >> 1815620

Effect of BIM-18216, a novel cholecystokinin receptor antagonist, on food intake reduction induced by cholecystokinin.

B Laferrere1, M Nguyen, G Bonhomme, A Legall, A Basdevant, B Guy-Grand.   

Abstract

The role of cholecystokinin (CCK) in food intake was investigated in rats by using BIM-18216, a novel CCK receptor antagonist. In rats fed 6 hr/day, BIM-18216 antagonized the reduction of food intake induced by exogenous CCK octapeptide (CCK-8; 4 micrograms/kg) in a dose-dependent manner and had a maximum effect at 1 mg/kg. BIM-18216 did not antagonize the effect of bombesin on food intake and showed some degree of specificity. BIM-18216 was not able to prevent the effect of endogenous CCK at the beginning of the feeding period. These data demonstrate that BIM-18216 is a potent CCK-specific antagonist. These results also suggest that endogenous and exogenous CCK could act by different regulating pathways.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1815620     DOI: 10.1037//0735-7044.105.5.707

Source DB:  PubMed          Journal:  Behav Neurosci        ISSN: 0735-7044            Impact factor:   1.912


  1 in total

1.  Neurobehavioural effects of SR 27897, a selective cholecystokinin type A (CCK-A) receptor antagonist.

Authors:  M Poncelet; M Arnone; M Heaulme; N Gonalons; C Gueudet; V Santucci; O Thurneyssen; P Keane; D Gully; G Le Fur
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-07       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.